Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 6/20 | 0.70 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.57 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.48 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | JAK1 | P23458 | 1/20 | 0.46 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.42 |
| ▸ | PTPRB | P23467 | 1/20 | 0.42 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | CETP | P11597 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13853353 | 0.80 | OPRM1 (0.60) | CCR5KCNH2HSD11B1OPRM1JAK2 | |
| SCHEMBL4138032 | 0.78 | CCR5 (0.65) | CCR5KCNH2OPRM1CHRM2CHRM3 | |
| SCHEMBL4123915 | 0.78 | CCR5 (0.81) | CCR5KCNH2OPRM1 | |
| SCHEMBL4123919 | 0.78 | CCR5 (0.81) | CCR5KCNH2OPRM1 | |
| SCHEMBL30532531 | 0.77 | JAK2 (0.52) | HSD11B1JAK2JAK1CHRM1CHRM2 | |
| SCHEMBL12094618 | 0.76 | JAK2 (0.65) | HSD11B1JAK2JAK1CHRM1CHRM2 | |
| SCHEMBL13896107 | 0.76 | JAK2 (0.65) | HSD11B1JAK2JAK1CHRM1CHRM2 | |
| SCHEMBL24535002 | 0.75 | SMN1; SMN2 (0.45) | CHRM1CHRM2CHRM3 | |
| SCHEMBL24534722 | 0.75 | SMN1; SMN2 (0.45) | CHRM1CHRM2CHRM3 | |
| SCHEMBL13853363 | 0.74 | CCR5 (0.55) | CCR5KCNH2HSD11B1OPRM1JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090124636-A1 | CHEMICAL COMPOUNDS | PFIZER INC. | 2009-05-14 | — | — | US | disclosed |
| US-20090124636-A1 | CHEMICAL COMPOUNDS | PFIZER INC. | 2009-05-14 | — | — | US | disclosed |
| US-20090124636-A1 | CHEMICAL COMPOUNDS | PFIZER INC. | 2009-05-14 | — | — | US | disclosed |
| WO-2007116313-A2 | PYRROLIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE CCR5 RECEPTORS | PFIZER LIMITED (GB) | 2007-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124636-A1 | CHEMICAL COMPOUNDS | CCR5, CXCR3, CX3CR1 | CCR5 1/4885KCNH2 810/4885HSD11B1 1718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.